

The NMR LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 5,343,389; 6,518,069; 6,576,471; 6,853,140; and 7,243,030. CLIA: 34D0952253



LipoScience, Inc.
2500 Sumner Boulevard
Raleigh, NC 27616
877-547-6837
www.liposcience.com

Page 1 of 1

Patient Name			Sex	Age	Clinician	
TEICHOLZ, NINA			F	49	DECHIARIO, ALAN	
Patient ID			Birth Date		Accession Number	
3055172			[REDACTED]		W2060421	
Client Name and Address						
Manhattan Physicians Lab 17139/ 25 Riverside Drive						
Pinebrook, NJ 07058 Phone: (973)575-0728 Fax: (973)575-0487						
Date Collected	Date Received	Report Date and Time		Requisition Number	Fasting Status	
05/12/2014	05/14/2014	05/14/2014 22:26			Not Specified	

NMR LipoProfile® test

	Percentile ¹	20th	50th	80th	95th	
LDL-P (LDL Particle Number)	nmol/L	Low	Moderate	Borderline-High	High	Very High
	1179	< 1000	1000-1299	1300-1599	1600-2000	> 2000

Lipids	mg/dL	Optimal	Near or above optimal	Borderline-High	High	Very High
LDL-C (calculated)	110	< 100	100-129	130-159	160-189	≥ 190

HDL-C	mg/dL	Triglycerides	mg/dL	Total Cholesterol	mg/dL
82	Desirable ≥ 40	67	Desirable < 150	205	Desirable < 200

LDL-C is inaccurate if patient is non-fasting.

Historical Reporting

LDL-P

05/12/14 (1179)

LDL-C

05/12/14 (110)

1. Reference population comprises 5,362 men and women not on lipid medication enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA). Mora, et al. *Atherosclerosis* 2007.

Faint header text at the top of the page, possibly containing a title or reference number.

First main paragraph of text, containing several lines of faint, illegible characters.

Second main paragraph of text, continuing the faint, illegible content.

Third main paragraph of text, with a small dark rectangular mark or redaction near the bottom left.

Fourth main paragraph of text, appearing as a block of faint, illegible characters.

Fifth main paragraph of text, continuing the faint, illegible content.

Sixth main paragraph of text, with a small dark rectangular mark or redaction near the bottom left.

Final paragraph of text at the bottom of the page, consisting of faint, illegible characters.

The NMA LipoProfile® test may be covered by one or more issued or pending patents, including U.S. Patent Nos. 5,343,389; 6,518,069; 6,576,471; 6,653,140; and 7,243,030. CLIA: 34D0952253




LIPOSCIENCE

LipoScience, Inc.
2500 Summer Boulevard
Raleigh, NC 27616
877-547-6837
www.liposcience.com

Page 1 of 1

Patient Name			Sex	Age	Clinician	
TEICHOLZ, NINA			F	49	DECHIARIO, ALAN	
Client Name and Address						
Patient ID			Birth Date		Accession Number	
3055172			05/07/1965		W2060421	
Manhattan Physicians Lab 17139/ 25 Riverside Drive						
Pinebrook, NJ 07056 Phone: (973)575-0728 Fax: (973)575-0487						
Date Collected	Date Received	Report Date and Time		Requisition Number	Fasting Status	
05/12/2014	05/14/2014	05/14/2014 22:26			Not Specified	

PARTICLE CONCENTRATION AND SIZE



These laboratory assays, validated by LipoScience, have not been cleared by the US Food and Drug Administration. The clinical utility of these laboratory values has not been fully established.

1. Garvey WT, et al. *Diabetes*. 2003; 52:453-462. 2. Golf DC et al. *Metabolism*. 2005; 54:264-270. 3. LipoScience reference population comprises 4,582 men and women without known CVD or diabetes and not on lipid medication.